Patisiran sodium

Art. -Nr.: HY-132609 Reinheit: 99.09%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA (G-Um-A-ACm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) sodium salt

Patisiran sodium Chemische Struktur

CAS. Nr. : 1386913-72-9

Größe	Verfügbarkeit	Menge
1 mg	Auf Lager	Estimated Time of Arrival: December 31
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Auf Lager	Estimated Time of Arrival: December 31
50 mg	Angebot einholen
100 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Patisiran sodium

•J Control Release. 2026 Mar 14:114825.

Spezialitätsempfehlungen

•Related Small Molecules:

•Related Proteins:

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung	Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis^[1]^[2]^[3].
In Vitro	Patisiran sodium causes TTR degradation (via RNA interference) and subsequently a reduction in serum TTR protein levels and tissue TTR protein deposits by specifically binding to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type transthyretin (TTR) messenger RNA^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Patisiran sodium Related Antibodies
Molekulargewicht	13424 (free acid)
CAS. Nr.	1386913-72-9
Appearance	Solid
Color	White to light yellow
Sequence	RNA, (A-U-G-G-A-A-Um-A-C-U-C-U-U-G-G-U-Um-A-C-dT-dT), complex with RNA (G-Um-A-ACm-Cm-A-A-G-A-G-Um-A-Um-Um-Cm-Cm-A-Um-dT-dT) (1:1) sodium salt
SMILES	[Patisiran (sodium)]
Versand	Room temperature in continental US; may vary elsewhere.
Speicherung	-20°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Lösungsmittel & Löslichkeit	In Vitro: H₂O : 33.33 mg/mL (Need ultrasonic) Molaritätsrechner Verdünnungsrechner Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Mass = Concentration × Volume × Molecular Weight * Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final) This equation is commonly abbreviated as: C₁V₁ = C₂V₂ Concentration _(start) C1 × Volume _(start) V1 = Concentration _(final) C2 × Volume _(final) V2 In Vivo Dissolution Calculator Please enter the basic information of animal experiments: Dosage mg/kg Animal weight (per animal) g Dosing volume (per animal) μL Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments. Calculation results: Working solution concentration: mg/mL This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details. The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE). Tel: 609-228-6898 E-mail: [email protected] Technical Support: [email protected]
Reinheit & Dokumentation	Purity: 99.09% Select Batch: Data Sheet (267 KB) SDS (251 KB) COA (244 KB) RP-HPLC (215 KB) MS (305 KB) Handling Instructions (2242 KB)
Verweise	[1]. Adams D, et, al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. [Content Brief] [2]. Hoy SM. Patisiran: First Global Approval. Drugs. 2018 Oct;78(15):1625-1631. [Content Brief] [3]. Kristen AV, et, al. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag. 2019 Feb;9(1):5-23. [Content Brief]